MilliporeSigma Licenses CRISPR Technology to Evotec
11.12.19
Will leverage CRISPR Portfolio to develop precisely engineered assays for potential drug candidates during the drug development cycle
MilliporeSigma has signed a license agreement providing Evotec SE access to its foundational CRISPR technology. Evotec, an international biotechnology company headquartered in Hamburg, Germany, will use MilliporeSigma's CRISPR genome-editing technology to create edited cell lines for Evotec's commercial and internal research purposes.
"This CRISPR license is the impetus for important drug testing and discovery that promises to accelerate research and lead to the development of new therapies," said Udit Batra, chief executive officer, MilliporeSigma. "MilliporeSigma has been at the forefront of innovation in gene editing for 15 years and continues to work with industry and academia to solve complex problems using our patented CRISPR technology, both ethically and responsibly."
Evotec plans to use MilliporeSigma's CRISPR Portfolio to develop precisely engineered assays to determine the biology and toxicity for potential drug candidates during the drug development cycle.
"Evotec is excited to continue its strong partnership with MilliporeSigma through licensing their groundbreaking CRISPR technology," said Craig Johnstone, chief operating officer of Evotec. "Our vision and passion for innovation includes using CRISPR technology to test and improve the translation of efficacy of the new drugs we develop to bring relief to patients suffering from underserved conditions worldwide."
"This CRISPR license is the impetus for important drug testing and discovery that promises to accelerate research and lead to the development of new therapies," said Udit Batra, chief executive officer, MilliporeSigma. "MilliporeSigma has been at the forefront of innovation in gene editing for 15 years and continues to work with industry and academia to solve complex problems using our patented CRISPR technology, both ethically and responsibly."
Evotec plans to use MilliporeSigma's CRISPR Portfolio to develop precisely engineered assays to determine the biology and toxicity for potential drug candidates during the drug development cycle.
"Evotec is excited to continue its strong partnership with MilliporeSigma through licensing their groundbreaking CRISPR technology," said Craig Johnstone, chief operating officer of Evotec. "Our vision and passion for innovation includes using CRISPR technology to test and improve the translation of efficacy of the new drugs we develop to bring relief to patients suffering from underserved conditions worldwide."
